Seqirus
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor, the company offers a diverse range of treatments to help ensure patients and people worldwide get the care they need. CSL is committed to continuous improvement to enhance life and public health.
Industries
Nr. of Employees
Very Large (1000+)
Seqirus
655 Elizabeth Street, Melbourne, VIC 3000, Australia
Products
Plasma-derived and recombinant therapeutic proteins
Therapeutic proteins produced from fractionated human plasma or recombinant expression for treatment of bleeding disorders, immunodeficiencies, hereditary angioedema and other rare diseases.
Influenza vaccines
Seasonal and pandemic influenza vaccines produced using egg- and cell-based manufacturing platforms and adjuvant formulations where applicable to address different population needs.
Therapies for iron deficiency and nephrology
Therapeutic products addressing iron deficiency and nephrology-related conditions, including options for dialysis-associated and rare disease indications.
Human serum albumin (excipient grade)
Excipient-grade human serum albumin supplied for pharmaceutical, biopharmaceutical and medical device manufacturing applications, including use in cell culture, cryopreservation, stabilisation and drug delivery formulations.
Fibrinogen and thrombin for manufacturing
Human-derived fibrinogen and thrombin supplied for use in scaffold fabrication, medical device coatings, cartilage regeneration and wound healing applications in pharmaceutical and medical device manufacturing.
Plasma-derived and recombinant therapeutic proteins
Therapeutic proteins produced from fractionated human plasma or recombinant expression for treatment of bleeding disorders, immunodeficiencies, hereditary angioedema and other rare diseases.
Influenza vaccines
Seasonal and pandemic influenza vaccines produced using egg- and cell-based manufacturing platforms and adjuvant formulations where applicable to address different population needs.
Therapies for iron deficiency and nephrology
Therapeutic products addressing iron deficiency and nephrology-related conditions, including options for dialysis-associated and rare disease indications.
Human serum albumin (excipient grade)
Excipient-grade human serum albumin supplied for pharmaceutical, biopharmaceutical and medical device manufacturing applications, including use in cell culture, cryopreservation, stabilisation and drug delivery formulations.
Fibrinogen and thrombin for manufacturing
Human-derived fibrinogen and thrombin supplied for use in scaffold fabrication, medical device coatings, cartilage regeneration and wound healing applications in pharmaceutical and medical device manufacturing.
Services
Country-specific channels for reporting suspected adverse events and global pharmacovigilance follow-up to fulfil safety reporting obligations to health authorities.
Online and phone complaint submission with standardised data capture (batch/lot, sample retention, photographs) and structured follow-up investigations for product quality or presentation issues.
Regional medical information contacts providing clinical, dosing and safety information to healthcare professionals via phone and email.
Customer service for product orders and logistics, including 24-hour emergency shipping for specified critical biologic products and logistics support for product issues.
Request-based supply of excipient-grade human serum albumin for pharmaceutical, biopharmaceutical and medical device manufacturing, with technical support and release documentation.
Request-based supply of fibrinogen and thrombin for use in scaffolds, device coatings, tissue engineering and wound healing applications, with partner-focused supply processes.
Country-specific channels for reporting suspected adverse events and global pharmacovigilance follow-up to fulfil safety reporting obligations to health authorities.
Online and phone complaint submission with standardised data capture (batch/lot, sample retention, photographs) and structured follow-up investigations for product quality or presentation issues.
Regional medical information contacts providing clinical, dosing and safety information to healthcare professionals via phone and email.
Customer service for product orders and logistics, including 24-hour emergency shipping for specified critical biologic products and logistics support for product issues.
Request-based supply of excipient-grade human serum albumin for pharmaceutical, biopharmaceutical and medical device manufacturing, with technical support and release documentation.
Request-based supply of fibrinogen and thrombin for use in scaffolds, device coatings, tissue engineering and wound healing applications, with partner-focused supply processes.
Expertise Areas
- Plasma-derived biologics manufacturing
- Influenza vaccine development and manufacturing
- Platform R&D: plasma proteins, recombinant proteins, cell & gene therapies
- Clinical trial design and conduct
Key Technologies
- Plasma fractionation
- Robotics and automation in biomanufacturing
- Recombinant protein expression
- Cell and gene therapy platforms
News & Updates
The Australian manufacturing site, which turns human plasma into critical medicines, was honored for its use of robotics and automation technologies.
CSL announced its half-year financial results, available with a webcast recording.
A platform sharing stories of biotech's promise to patients and public health, including community impact awards and rare disease studies.
CSL's sustainability strategy includes reducing emissions, supporting communities, and fostering inclusion and belonging.
CSL emphasizes innovation through awards, grants, and a global R&D network, focusing on plasma protein technology, recombinant technology, cell and gene therapy, and vaccines.
CSL's plasma fractionation facility was awarded for its full-scale use of robotics and automation.
The Australian manufacturing site, which turns human plasma into critical medicines, was honored for its use of robotics and automation technologies.
CSL announced its half-year financial results, available with a webcast recording.
A platform sharing stories of biotech's promise to patients and public health, including community impact awards and rare disease studies.
CSL's sustainability strategy includes reducing emissions, supporting communities, and fostering inclusion and belonging.
CSL emphasizes innovation through awards, grants, and a global R&D network, focusing on plasma protein technology, recombinant technology, cell and gene therapy, and vaccines.
CSL's plasma fractionation facility was awarded for its full-scale use of robotics and automation.